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Abstract: 
Pneumococcal pneumonia is a significant disease that requires rapid treatment with effective 
antibiotics.  This study attempts to identify associations with clinical and laboratory 
parameters from pneumococcal pneumonia cases from the University of Kansas Hospital 
during the years 1996 to 2005 that can be used to identify appropriate antibiotic therapies.  
Antibiotic resistance profiles together with retrospective chart reviews were used to identify 
associations.  This study found no association between multi-drug non-susceptibility and 
mortality and no association between classification of pneumonia acquisition in individual 
groups (CAP, HCAP, HAP, VAP) and mortality.  This study did find an association between 
multi-antibiotic non-susceptibility in isolates from patients who acquired pneumonia in a 
healthcare setting (HCAP, HAP, VAP).  These results suggest the possibility that patients 
who frequently need healthcare may be more likely to have empiric antibiotic therapy. This 
may then be associated with carriage of more antibiotic resistant SPN isolates.  The empiric 
antibiotic therapy should be reviewed frequently to provide the best therapy for patients 
while reserving the other antibiotics for the more acute cases of resistant pneumococcal 
disease. 
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Introduction: 
Streptococcus pneumoniae is a major cause of community-acquired pneumonia (CAP). [File 
2003, File 2004]   There are approximately 135,000 hospitalizations due to pneumococcal 
pneumonia each year and 14% of these patients die from this infection. [CDC 2006]  
Pneumonia is a very serious disease and rapid initial antibiotic therapy can be life saving.  
However, it is difficult to determine appropriate antibiotic therapy for serious, life 
threatening cases of S. pneumoniae (SPN) since this bacteria has developed antibiotic 
resistance to several first line antibiotics  [Skalet 2010, Van Eldere 2007, Croucher 2011]. 
Antibiotic resistance and mortality associations have been studied in pneumococcal 
pneumonia for single antibiotics [Pallares 1995, Feilkin 2000], and 2 or more antibiotics 
[Arredondo-Garcia 2011, Aspa 2004, Bonnard 2005, Valles 2006] but no study has analyzed 
mortality associations with antibiotic resistance of pneumococcal pneumonia by the 2 multi-
drug non-susceptibility groups of penicillin and macrolide; penicillin, macrolide and 
sulfonamide or the non-susceptibility rates for these 2 multi-drug non-susceptibility groups 
by category of pneumococcal pneumonia categories. 
Mortality rates have been compared between pneumococcal pneumonia categories of CAP 
and HCAP [Micek 2007], between pneumococcal pneumonia categories of CAP and HAP 
[Feilkin 2000], between all cause HAP and VAP [Esperatti 2010] as well as mortality 
between all pneumonia categories including all causative agents [Kollef 2005]. However, the 
assessment of mortality rates of pneumococcal pneumonia by all categories (CAP, HCAP, 
HAP and VAP) has not been reported. 
The current study analyzes SPN isolates from hospitalized adult patients with SPN 
pneumonia.   The antibiotic non-susceptibility rate was analyzed in association with mortality 
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as well as the category of pneumococcal pneumonia acquisition.  Additionally the category 
of pneumococcal pneumonia acquisition was analyzed for association with mortality. 
 
Background: 
S. pneumoniae is a bacterium that commonly colonizes the oral-pharyngeal area of several 
mammals including humans [Austrian 1986, Hendley 1975].  It can be transmitted person to 
person by airborne droplets.  However, this bacterium can also cause a serious pneumonia in 
humans.  Pneumonia due to SPN can occur either in the community and become serious 
enough to result in the hospitalization of patients.  These pneumonias are classified as either 
community acquired pneumonia (CAP). The definition of CAP is the development of 
pneumonia in a patient that has not been hospitalized in the last 6 months and does not have a 
chronic disease.  
A separate group of patient may have serious underlying health problems and acquire SPN 
pneumonia outside of the hospital. These patients are considered to have health care 
associated pneumonia (HCAP) with SPN. HCAP is defined as the development of 
pneumonia outside the hospital but satisfying one or more of the following conditions:  
previously hospitalized within 90 days of developing pneumonia; residence in a nursing 
home or long-term care facility; receipt of intravenous antibiotic therapy, chemotherapy or 
wound care within 30 days and/or attended a hospital or hemodialysis clinic. [ATS 2005] 
In addition patient hospitalized for non-pneumonia reasons can develop SPN pneumonia 
while in the hospital. This study analyzes SPN pneumonia acquired both outside or after 
hospitalization.   The data from the various categories of SPN pneumonias will be compared 
to hospital-acquired pneumonia (HAP) in which the patient was hospitalized for a medical 
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reason that was not pneumonia and developed SPn pneumonia 48 hours or more after 
admission to the hospital. A subset of HAP is ventilator-associated pneumonia (VAP), which 
is the development of pneumonia 48 to 72 hours after intubation. Patients with SPN 
pneumonias meeting this criterion were analyzed as a separate subset than those patients with 
HAP. These categories allow for a valuable comparison of adult patients with SPN 
pneumonia that required hospitalization.  [ATS 2005, Kollef 2008]  
This study evaluated the association of antibiotic resistance, mortality, and the category of 
pneumonia  (CAP, HCAP, HAP and VAP).  Specifically, this study evaluated whether multi 
drug non-susceptibility is associated with mortality in patients with pneumococcal 
pneumonia. Additionally it will be determined if the category of pneumonia is associated 
with an increase in mortality in pneumococcal pneumonia patients and if the category of 
pneumonia is associated with multi-drug non-susceptibility in SPN. 
 
Methods:  
Study Design: 
This study was conducted at the University of Kansas Medical Center Department of 
Pathology and Laboratory Medicine between 2002 and 2005.  A retrospective chart review 
was conducted for all SPN isolates in storage.  The data from the retrospective chart review 
was entered into the research database and linked to the SPN isolate in freezer storage.  The 
data was de-identified after matching to the isolate in storage.   
Definition of pneumonia: 
Subjects were classified as having pneumonia if the chart review of the episode when the 
sample was collected indicated: fever, tachypnea (respiration rate of 24-30 breaths/minute), 
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Tachycardia (heart rate > 100 beats / minute), rales, thick and purulent sputum that was 
described as rust colored and had a Gram stain showing Polymorphic Neutrophils and 
bacteria, a white blood cell count of 15,000 – 30,000/mm3, abnormal chest x-ray, moderate 
hypoxia due to ventilation/perfusion abnormalities.  
Identification and characterization of Bacterial isolates: 
Strains of SPN isolated from patients at the University of Kansas Hospital from 1996 through 
2005 were collected and frozen at -70ºC.  These isolates were later tested for antibiotic 
resistance using e-Strips (Remel) in five classes of antibiotics: penicillin, cephalosporin, 
macrolide, sulfonamide, quinolone.  The minimum inhibitory concentrations (MIC) for each 
strain were classified into susceptible, intermediate, and resistant based on the 1999 National 
Committee on Clinical Laboratory Standards (NCCLS) MIC breakpoints. 
Identification of Clinical Inclusion and Exclusion Criteria: 
Retrospective chart review was performed and clinical data was collected related to each 
patient infected with SPN such as age of patient at the time of SPN isolation, radiographic 
and/or clinical signs or symptoms of pneumonia, whether or not a positive blood culture was 
also present at the time of SPN isolation, mortality, length of stay, and using the information 
in the medical chart, each case of pneumonia was categorized as to the location of acquisition 
of the disease.   
Only those SPN isolates obtained from patients who were age 18 or greater at the time of 
collection of the specimen positive for SPN and who were determined to have a case of 
pneumonia at the time of specimen collection and who were hospitalized were included in 
the analysis (see Figure 1 and Table 1). 
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Calculations: 
For the purposes of calculating drug resistance percentages, if a particular strain had not been 
challenged in the laboratory by a particular class of antibiotics the strain was not counted in 
the total number of strains.  All antibiotic analysis of percentage of non-susceptible strains 
used the following formula: 
 
# of intermediate + # of resistant 
     100%   * 
# of susceptible + # of intermediate + # of resistant 
 
Also in the case of multiple drug resistance calculations if a strain was not challenged by all 
of the antibiotic classes in question it was not included in the numerator nor in the 
denominator of the equation. 
Isolates were classified into susceptible and non-susceptible categories by collapsing 
intermediately susceptible isolates into the non-susceptible category. 
Chi Square analysis and Fisher’s Exact Test were done using statistical analysis software 
SAS (see appendix 1).  
 
Results: 
Patient Population: 
After chart review 424 SPN isolates met the inclusion criteria.  Of these isolates, 174 
(41.04%) came from patients who acquired the pneumonia from the community (CAP), 98 
(23.11%) were from health care associated pneumonia (HCAP), 64 (15.09%) were from 
hospital-acquired pneumonia (HAP), 88 (20.75%) were from ventilator-associated 
pneumonia (VAP). (See Table 1) 
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Mortality by Multi-Drug Non-Susceptibility: 
420 isolates were tested with penicillin and macrolide drugs in vitro for susceptibility.  Only 
238 isolates were tested with penicillin, macrolide and sulfonamide drugs in vitro. 
Of the 420 isolates that were challenged by both penicillin and macrolide drugs 93 were non-
susceptible to both. Of those 93 that were non-susceptible, 10 isolates came from patients 
who died during hospitalization giving a mortality rate of 10.8% associated with SPN isolates 
non-susceptible to both penicillin and macrolide drugs.  The mortality rate for all isolates that 
were challenged by penicillin and macrolide drugs was 12.1%. It appears that resistance to 
penicillin and macrolide drugs in vitro is not associated with an increase in mortality rate. 
Of the 238 isolates that were challenged by penicillin, macrolide and sulfonamide drugs 47 
were non-susceptible  (19.8%). Of the 47 SPN that were non-susceptible to these drugs, 6 
isolates came from patients who died during hospitalization giving a mortality rate of 12.8%.  
The mortality rate of all isolates that were challenged by penicillin, macrolide and 
sulfonamide drugs was 13.4% (see table 2).  It appears that resistance to penicillin, macrolide 
and sulfonamide drugs in vitro is not associated with an increase in mortality rate. 
Mortality by category of Pneumonia: 
The total population of 424 isolates used in this analysis included 51 isolates that came from 
patients who died during hospitalization giving an overall mortality rate of 12.0% (Table 3).  
Individually no particular category (CAP, HCAP, HAP, VAP) showed a statistically 
significant higher mortality rates. (χ2 analysis p-value = 0.436) 
When the health care associated categories are collapsed (Table 4) there is a no significant 
difference in mortality rates between the two categories (Fisher’s Exact Test p-value 0.1716).  
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Drug Non-Susceptibility by category of Pneumonia: 
The data shown in Table 5 show the raw number of isolates considered non-susceptible to 
each drug with the percentage of non-susceptibility to each of 5 classes of antibiotics as well 
as two multi-drug categories.  The raw data show that those categories associated with health 
care (HAP and VAP) have higher rates of antibiotic non-susceptibility. It may be that 
previous therapies for the current incident and for co-morbidities make it valuable to collapse 
data between true community-acquired pneumonia and that associated with some form of 
health care.  Table 6 shows the two multi-drug classes and the non-susceptibility as collapsed 
into 2 categories of disease. The Fisher’s Exact test shows that HCAP/HAP/VAP group 
(which generally includes patients with higher co morbidities) and the CAP group have a 
statistically significant difference in having SPN isolates with 2 different drug non-
susceptibility (Fisher’s Exact test p-value 0.0027) and with 3 antibiotic non-susceptibility 
markers (Fisher’s Exact test p-value 0.0029). 
 
Discussion: 
Mortality by Multi-Drug Non-Susceptibility: 
In this study, antibiotic resistance to any one specific drug was not associated with a change 
in mortality rate.  Multi-drug categories were created based on antibiotic therapies considered 
to be commonly found in SPN. These multiresistant SPN have increased in the last 10 years. 
The mortality rates among patients infected with SPN strains susceptible to penicillin and 
macrolides showed no significant difference in mortality rates when compared to patients 
infected with isolates non-susceptible to penicillin and macrolides.  The mortality rates of 
patients infected with SPN that are susceptible to penicillin, macrolides and sulfonamides 
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were not significantly different than that of isolates that were non-susceptible to penicillin, 
macrolides and sulfonamides. The limitation of this study may be due to the number of 
isolates challenged by sulfonamides, which could result in insufficient data to assess the 3-
drug non-susceptibility category for an increase in mortality rate.  However, researchers in 
Mexico also found a “slightly higher” mortality rates among multi-drug resistant SPN 
[Arredondo-Garcia 2011]. Other studies have found that there is mortality rates were not 
increased in patients infected with multi-drug non-susceptibility SPN isolates [Aspa 2004, 
Bonnard 2005, Valles 2006]. 
A possible explanation for the lack of an association between mortality and multi-drug 
resistance in this study may be that 59% of the subjects included in the current study were 
under medical treatment on presentation or had received medical treatment within the last 3 
months before the pneumococcal pneumonia diagnosis.  It is possible that attending 
physicians were aware of current or recent antibiotic therapies and begin treatment with 
alternative antibiotic therapies sooner thereby preventing mortality in these patients. 
Mortality by category of Pneumonia: 
No statistically significant difference in mortality was noted among patients in individual 
categories of pneumonia (CAP, HCAP, HAP, VAP) nor the collapsed groups of CAP vs 
HCAP/HAP/VAP.  This may be due to the fact that people with CAP may wait until the 
disease has progressed significantly before seeking medical care however this analysis has no 
data to assess this possibility.  Pneumococcal CAP and HCAP rates published by Micek in 
2007 showed a higher pneumococcal CAP mortality than that of pneumococcal HCAP. 
However, Micek did not present any statistical analysis to determine whether or not the 
difference was significant.  The comparison of HAP and CAP published by Feikin in 2000 
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did show a significantly different rate of mortality between pneumococcal CAP and 
pneumococcal HAP.  The definitions of category of pneumococcal disease only included the 
time from admission to the time of collection of a specimen positive with SPN.  This may 
indicate that cases in the current study defined as VAP could be included in HAP. This 
would account for more severe cases included in Feikin’s HAP leading to a higher mortality 
rate which appears to be more significant. This would therefore not truly be comparable to 
the analysis of all 4 categories found in this study. 
Drug Non-Susceptibility by category of Pneumonia: 
When non-susceptibility SPN were analyzed and evaluated in each separate category of 
pneumonia no  antibiotic had a statistical significantly difference in the rate of multi drug 
non-susceptibility (including isolates with only 2 multi-drug non-susceptibility rates). 
When the HCAP, HAP and VAP categories were combined into one category and the drug-
non-susceptibility was compared to patients in the CAP category, the results showed that the 
HCAP/HAP/VAP had significantly higher rates of multi-drug non-susceptibilities (2-drug 
resistance Fisher’s Exact test p-value 0.0027 and 3-drug resistance Fisher’s Exact test p-
value 0.0029).  This may be explained by the SPN having encountered multiple classes of 
antibiotics in the course of treatment and that these patients had more co-morbidities 
including chronic disease that exposed them to multiple courses of antibiotic therapy.  No 
published research could be found that assessed all 4 classes of pneumococcal pneumonia 
and compared the rates of non-susceptibility in SPN.  Several researchers published 
resistance rates among hospitalized patients but did not provide an evaluation of outcomes by 
the category of pneumonia.  A recent study from Mexico indicated that SPN isolates from 
hospitalized children collected between 2002 and 2005 noted that 41% of these children were 
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infected with SPN resistant to Penicillin, while 43% of the SPN had resistance to macrolides 
while 58% were resistant to sulfonamides [Arredondo-Garcia 2011]. Another report from 
Japan found that for patients in their nationwide surveillance with respiratory tract infections 
between January 2008 and April 2008 47.4% of SPN isolates were non-susceptibility to 
penicillin and that there was a “high frequencies of resistance to macrolides.” [Niki 2011]  
Research from Taiwan showed that among all hospitalized patients including patients seen in 
the emergency services and outpatient clinics from 1999 to 2005 that 39.4% of SPN isolates 
were non-susceptibility to penicillin, while 92% of isolates were non-susceptibility to 
macrolides. .  The Taiwan isolates include SPN collected from any body sites and was not 
restricted to respiratory infections. [Lo 2011]  It is likely that the differences in resistance 
rates between our research and the others listed above (Arrendondo-Garcia, Niki and Lo) 
reflects the differences in the use of certain antibiotics as empiric therapy. Additional studies 
would be useful if they included the antibiotic recommendations for use in CAP versus the 
antibiotics that are recommended in the institution for hospital/healthcare associated 
pneumonias.  Antibiotic algorithms can vary between countries as well as types of 
institutions. This variability in therapy choices will affect the amount and type of antibiotic 
exposure that circulating SPN encounter. 
 
Conclusion: 
At the University of Kansas Hospital from 1996-2005 SPN isolates from patients with 
healthcare associated, hospital acquired and ventilator associated pneumonia cases show a 
significantly higher rate of multiple drug non-susceptibility than isolates from patients 
infected outside the health care system (Community Acquired pneumonia).  
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The healthcare community continues to struggle to strike a balance between the use an 
antibiotic therapy that is sufficient to treat the pneumonia yet still reserves the most powerful 
antibiotic therapy for the more resistant bacterial strains.  Many researchers, healthcare 
providers and government institutions (CDC) have called for a judicious use of antibiotics to 
curb the multi-drug resistance that is prevalent in SPN worldwide [Harboe 2010, Lo 2011, 
Niki 2011, Matsumoto 2010, Welte 2010]. Our healthcare facilities must continue to 
carefully monitor infection control procedures which will reduce the transmission of bacterial 
strains. Additional research should be conducted to find other ways to rapidly identify the 
isolates that are multiply resistant and determine which patients are most at risk of carrying 
multiply resistant isolates.  When designing future studies it may be beneficial to include post 
hospitalization mortality data when available.  Other studies have indicated that mortality 
post hospitalization may be an important consideration [Kaplan 2003, Koivula 1999, 
Niederman 2007] when reviewing the true affects of pneumonia on patients.  Some 
researchers have indicated that c-reactive protein [Almirall 2004] and procalcitonin 
[Bousskey 2006, Masia 2005] may also be important markers in the severity and progress of 
pneumonia.  These markers should be included in future research.   Furthermore, empiric 
therapy should be re-assessed frequently to capture current trends in the disease state as well 
as the resistance of microbes currently circulating in the population.   
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Figures and Tables: 
Figure 1 
1108 
780 
672 
424 
Total SPn Isolates From Adults With Pneumonia Who were 
Hospitalized 
Inclusion Screening 
 
 
Table 1 
 
 
 
 
 
 
S. pneumoniae Pneumonia Classification 
  CAP HCAP HAP VAP Total 
# of Cases 174 98 64 88 424 
% of Whole 41.04% 23.11% 15.09% 20.75% 100.00% 
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Table 2 
Multi Drug Non-Susceptibility and Mortality Rates 
  Non-Susceptible Susceptible All 
Penicillin + 
Macrolide 
10 deaths /93 non-
susceptible 
41 deaths /327 
susceptible 
51 deaths /420 
challenged 
Mortality Rate 
(10.8%) Mortality Rate (12.5%) 
Mortality Rate 
(12.1%) 
Penicillin + 
Macrolide + 
Sulfonamide 
6 deaths/47 non-
susceptible 
26 deaths /191 
susceptible 
32 deaths /238 
challenged 
Mortality Rate 
(12.8%) Mortality Rate (13.6%) 
Mortality Rate 
(13.4%) 
 
Table 3 
S. pneumoniae Pneumonia Mortality by Pneumonia Category 
  CAP HCAP HAP VAP Total 
# of Cases 174 98 64 88 424 
Mortality 16/174 (9.2%) 13/98 (13.3%) 8/64 (12.5%) 14/88 (15.9%) 51/424 (12.0%) 
 
Table 4 
S. pneumoniae Pneumonia Mortality using collapsed 
HCAP/HAP/VAP categories versus CAP 
  CAP HCAP/HAP/VAP Total 
# of Cases 174 250 424 
Mortality 16/174 (9.2%) 35/250 (14 %) 51/424 (12.0%) 
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Table 5 
Non-Susceptible S. pneumoniae Pneumonia by Pneumonia Category 
 CAP HCAP HAP VAP Total 
Penicillin 49/172 (28.5%) 32/98 (32.7%) 31/64 (48.4%) 39/88 (44.3%) 151/422 (35.8%) 
Cefalosporin 4/172 (2.3%) 1/98 (1%) 2/64 (3.1%) 6/88 (6.8%) 13/422 (3.1%) 
Macrolide 33/171 (19.3%) 28/97 (28.9%) 22/64 (34.4%) 33/88 (37.5%) 116/420 (27.6%) 
Quinilone 4/171 (2.3%) 4/98 (4.1%) 3/64 (4.7%) 1/88 (1.1%) 12/421 (2.9%) 
Sulfonamide 25/102 (24.5%) 17/58 (29.3%) 9/31 (29%) 28/47 (59.6%) 79/238 (33.2%) 
Penicillin + 
Macrolide 25/171 (14.6%) 19/97 (19.6%) 22/64 (34.4%) 27/88 (30.7%) 93/420 (22.1%) 
Penicillin + 
Macrolide + 
Sulfonamide 11/102 (10.8%) 9/58 (15.5%) 8/31 (25.8%) 19/47 (40.4%) 47/238 (19.8%) 
  
Not all isolates were challenged by all antibiotic classes. The cells contain the raw 
number of non-susceptible isolates / the raw number of isolates challenged by the drug(s) 
followed by the (calculated percentage of non-susceptibility). 
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Table 6 
 Multi-Drug Non-Susceptable S. pneumoniae 
Using collapsed HCAP/HAP/VAP categories versus CAP 
  CAP HCAP/HAP/VAP Total 
Penicillins + 
Macrolides 25/171 (14.6%) 68/249 (27.3%) 93/420 (22.1%) 
Penicillins + 
Macrolides + 
Sulfonomide 11/102 (10.8%) 36/136 (26.5%) 47/238 (19.7%) 
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Appendix 1: 
dm 'log;clear;output;clear'; 
 
PROC IMPORT OUT= WORK.nat  
          DATAFILE= "C:\Documents and Settings\autologon\My Documents\ 
 
Downloads\Thesis Files\Thesis Files\Adult Pneumo Natalie Thesis.csv"  
            DBMS=CSV REPLACE; 
     GETNAMES=YES; 
     DATAROW=2;  
RUN; 
 
data nat; 
 length locacq2 $15 Location_of_Spn_Aquisition $4 pms $3.; 
 format Location_of_Spn_Aquisition $4.; 
 set nat; 
 where collection_date ^= . and box_number ^= ''; 
 Location_of_Spn_Aquisition = tranwrd(Location_of_Spn_Aquisition,'HCA','HCAP'); 
 if Location_of_Spn_Aquisition in('HAP','HCAP','VAP') then locacq2 = 
'HCAP/HAP/VAP'; 
 else if Location_of_Spn_Aquisition = 'CAP' then locacq2 = 'CAP'; 
 if pen_macro ^='N' and not_p_m_tested = '' then pm = 'Y'; 
 else pm = pen_macro; 
 if pen_macro_sulfa ^= 'N' and not_pm_s_tested = '' then pms = 'Y'; 
 else pms=pen_macro_sulfa; 
run; 
 
proc freq; 
 tables locacq2*Location_of_Spn_Aquisition;run; 
*table 3; 
proc freq data=nat; 
 tables patient_expired*Location_of_Spn_Aquisition /chisq; 
run; 
*table 4; 
proc freq data=nat; 
 tables patient_expired*locacq2 /fisher; 
run; 
*table 6; 
proc freq data=nat; 
 tables pm*locacq2 /fisher; 
run; 
proc freq data=nat; 
 tables pms*locacq2 /fisher; 
run; 
 
